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Cells in homeostasis metabolize glucose mainly through the tricarboxylic acid cycle and
oxidative phosphorylation, while activated cells switch their basal metabolism to aerobic
glycolysis. In this study, we examined whether metabolic reprogramming toward aerobic
glycolysis is important for the host response to Mycobacterium tuberculosis (Mtb). Through
transcriptional and metabolite analysis we show that Mtb induces a switch in host cellu-
lar metabolism toward aerobic glycolysis in human peripheral blood mononuclear cells
(PBMCs). Themetabolic switch is TLR2 dependent but NOD2 independent, and ismediated
in part through activation of the AKT-mTOR (mammalian target of rapamycin) pathway.
We show that pharmacological inhibition of the AKT/mTOR pathway inhibits cellular
responses to Mtb both in vitro in human PBMCs, and in vivo in a model of murine tuber-
culosis. Our findings reveal a novel regulatory layer of host responses to Mtb that will aid
understanding of host susceptibility to Mtb, and whichmay be exploited for host-directed
therapy.
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Introduction
In the absence of HIV coinfection, it is mostly unknownwhat deter-
mines susceptibility to Mycobacterium tuberculosis (Mtb), which
accounts for almost two million deaths annually.
Recent studies suggest that immune activation and cellular
energy metabolism may be relevant since changes in metabolism
profoundly influence cell fate and effector functions. For example,
it has been shown that changes in glucose metabolism influence
T-cell lineage polarization, innate and adaptive cellular memory
and even protein transport, and secretion in response to cellu-
lar activation [1–4]. Na¨ıve and tolerant cells appear to primarily
rely on the tricarboxylic acid (TCA) cycle and oxidative phospho-
rylation for metabolizing glucose and generating stores of ATP
necessary for cell survival and function. Upon activation however,
a switch toward aerobic glycolysis rewires intracellular glucose
metabolism [5]. This permits a significant increase in ATP pro-
duction and, through the pentose phosphate pathway, provides
the nucleotides necessary for cell proliferation [6]. Recent studies
by Shi et al. and Gleeson et al. have shown that a shift toward
glycolysis is an important component of host defence in murine
models of tuberculosis [7, 8]. Taking these studies further, we
have investigated which cells, receptors, and regulators promote
the Mtb-induced switch to glycolysis in humans. We have tested
our hypotheses both in in vitro and in vivo experimental models
and verified whether such metabolic reprogramming also occurs
in patients with active pulmonary TB.
Results
Transcriptome analysis of TB patients and human
Mtb-stimulated PBMCs show a shift toward glycolysis
Based on expression of genes coding for glycolysis or TCA cycle
pathways, pulmonary TB patients (PTB) could be clearly sepa-
rated from individuals with latent tuberculosis infection (LTBI)
or healthy controls (CON) using principal component analysis of
publically sourced human expression data [9] (Fig. 1A and B).
Regression analysis on the first component of both groups showed
that both pathways were significantly different between LTBI and
PTB (p < 0.001 for both) groups. Individuals on antituberculosis
treatment were spread throughout the plot with untreated cases
closer to PTB and those on 12 months of treatment interspersed
with the LTBI and CON groups. Analysis of individual genes in the
PTB versus CON groups clearly showed an upregulation of glycol-
ysis genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and hexokinase-3 (Fig. 1C and D), which returned toward nor-
mal following treatment. The opposite was observed for the TCA
cycle gene isocitrate dehydrogenase 3 (NAD+) beta (IDHB3B)
(Fig. 1E).
We next examined expression of similar metabolic genes in an
in vitro model. Similar to the in vivo dataset described above,
Mtb-stimulated peripheral blood mononuclear cells (PBMCs)
also displayed a strong upregulation of some genes involved in
glycolysis and downregulation of some involved in the TCA cycle
(Fig. 1F).
Based on the in vitro and in vivo data analyses, an intracellu-
lar map was generated to reflect the switch to aerobic glycolysis
induced upon Mtb stimulation (Fig. 1G). The general metabolic
shift is further supported by altered expression of individual genes.
SLC16A3 (solute carrier family 16 monocarboxylate transport
MCT, member 3), which encodes a lactate transporter, was signif-
icantly upregulated in PTB patients and returned to normal levels
upon treatment (Supporting Information Fig. 1A). Conversely, sir-
tuin 5 (SIRT5), a protein whose activity is directly linked to the
energy status of the cell via the cellular NAD+/NADH ratio, was
downregulated in PTB patients and normalized upon treatment
(Supporting Information Fig. 1B).
Mtb drives cellular commitment to aerobic glycolysis
in human monocytes and macrophages
Monocytes, macrophages, dendritic cells (DCs), T helper (TH)1,
and TH17 cells use glucose as a substrate for energy produc-
tion [10]. To determine the commitment to glycolytic metabolism
in stimulated monocytes, we analyzed the extracellular acidifi-
cation rate (ECAR) as an indicator of the glycolytic rate 24 h
poststimulation. There was a significant increase in all three base-
line measurements and ECAR levels were approximately 3.3-fold
higher in Mtb-stimulated cells (Fig. 2A). This increase in ECAR
was responsible for a decrease in the oxygen consumption rate
(OCR)/ECAR ratio, as previously described for LPS [11] (Support-
ing Information Fig. 2A), despite a slightly higher OCR (Fig. 2B).
Similarly, macrophages infected with live Mtb or stimulated
with Mtb lysate produced increased levels of lactate, one of the
hallmarks of glycolysis (Fig. 2C). Additionally, PBMCs challenged
with Mtb showed increased glucose consumption (Fig. 2D) and
lactate production (Fig. 2E). Generation of lactate requires the
oxidation of NADH to cofactor NAD+ by lactate dehydrogenase.
Accordingly, we observed a significant increase in the ratio of
NAD+/NADH in Mtb-stimulated PBMCs (Fig. 2F). Conversely,
resting PBMCs displayed a lower NAD+/NADH ratio reflecting
cellular metabolism mostly via the TCA cycle rather than glycoly-
sis (Fig. 2F).
Mtb activates AKT and mTOR in human PBMCs
As mammalian target of rapamycin (mTOR) is the master regula-
tor of cell growth, proliferation, and metabolism, [12] and AKT-
mediated mTOR activation induces glucose metabolism, [13, 14]
we assessed whether Mtb activated the AKT-mTOR pathway
(Fig. 3A). Indeed, sensing of the microorganism induced AKT acti-
vation, which was inhibited by the phosphatidylinositol-3 kinase
(PI-3K) inhibitor wortmannin (Fig. 3B). In addition, p70-S6K and
4E-BP1, two canonical downstream targets of mTOR, were acti-
vated uponMtb stimulation. Purification of CD14+ monocytes and
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CD3+ T cells from stimulated PBMCs revealed that Mtb induced
mTOR activation in monocytes but not T cells (Fig. 3C). Activa-
tion of these mTOR targets was inhibited by rapamycin, an mTOR
inhibitor, in both PBMCs (Fig. 3D) and CD14+ monocytes (Sup-
porting Information Fig. 3A).
Additionally, rapamycin, torin, and wortmannin significantly
decreased lactate release induced by Mtb, further demonstrating
the involvement of the mTOR/AKT pathway in induction of gly-
colysis by Mtb (Fig. 3E–G).
mTOR regulates TH-cell-derived cytokines from
PBMCs in response to Mtb
T lymphocytes form a crucial component of the host defence
against Mtb. Direct inhibition of glycolysis by 2-deoxy-glucose
led to a dose-dependent decrease in the production of the TH
cytokines interferon gamma (IFN-γ), interleukin (IL) 17, and
IL-22 from PBMCs in response to Mtb (Fig. 4A). Direct inhi-
bition of mTOR by rapamycin or torin or indirectly by AICAR
(an AMPK activator; Fig. 4B and C), and inhibition of mTOR-
dependent HIF-1α activation by ascorbate also resulted in reduced
TH-derived cytokine production (Fig. 4D). IL-10 production in
response to Mtb was also significantly inhibited upon mTOR inhi-
bition (Supporting Information Fig. 4A, B, and D). Production of
monocyte-derived tumor necrosis factor (TNF) α, IL-6, and IL-1β
was mostly reduced upon inhibition of glycolysis with 2-deoxy-
glucose (Supporting Information Fig. 4A). Interestingly, produc-
tion ofmonocyte-derived cytokines remainedmostly unchanged in
the presence of rapamycin, torin, and ascorbate (Supporting Infor-
mation Fig. 4B–D). These inhibitors did not affect cell survival at
the time points used for the stimulation experiments (Supporting
Information Fig. 5A–E).
Induction of glycolysis by Mtb is TLR2 dependent but
NOD2 independent
Wenext examinedwhich of themain pattern recognition receptors
(PRRs) that mediate recognition of Mtb, [15] are necessary for a
metabolic switch toward aerobic glycolysis. PBMCs isolated from
patients with a complete deficiency in NOD2 showed decreased
cytokine production in response to Mtb (Fig. 5A), but no decrease
in lactate production (Fig. 5B). In addition, bone marrow (BM)
derived macrophages (BMDMs) from NOD2 knockout (NOD2−/−)
and NOD1/NOD2 double knockout (NOD1−/−/NOD2−/−) mice
stimulated with Mtb showed decreased KC and IL-6 produc-
tion. However, as with the NOD2-deficient patients, no change
in lactate production was observed and no major differences
were apparent after stimulation of BMDMs from NOD1 knockout
(NOD1−/−) mice either (Fig. 5C and D).
We then examined possible synergy with regard to lactate pro-
duction between NOD2 and the TLRs involved in recognition of
Mtb. As expected, cytokine production of PBMCs stimulated with
LPS (TLR4 ligand), Pam3Cys (P3C, TLR2 ligand), orMtb increased
in the presence of muramyl dipeptide (MDP, an NOD2 ligand),
while MDP by itself did not induce cytokine production (Fig. 6A
and B). On the other hand, MDP showed no synergistic effect for
lactate production upon stimulation with the various other TLR
ligands (Fig. 6C).
To investigate the role of TLR4 in the induction of aerobic
glycolysis by Mtb, we blocked TLR4 by preincubation of PBMCs
with Bartonella quintana LPS, a potent natural antagonist of TLR4
(Popa et al., [16]), before stimulating with Mtb or Escherichia coli
LPS. Although a potent decrease in IL-6 and lactate levels was
observed for LPS, indicating effective blocking of TLR4, no effect
of the TLR4 blockade on Mtb-induced lactate was seen (Fig. 6D
and E).
To investigate the role of TLR2, we stimulated BMDMs and
peritoneal macrophages from TLR2 knockout (TLR2−/−) mice
with Mtb and Pam3Cys. Production of KC (IL-8) and lactate was
potently decreased in TLR2−/− BMDMs compared to wild-type
(WT) controls (Fig. 6F–H). In addition, stimulation of cells isolated
from TLR2−/− mice with Mtb led to a decrease in AKT activation
compared to controls, while the induction of AKT with insulin,
in a TLR-independent manner, was unaffected (Fig. 6I). Collec-
tively, these data implicate TLR2, and not TLR4 or NOD2, as the
major PRR that induces AKT/mTOR pathway activation and thus
mediates the switch to aerobic glycolysis upon Mtb stimulation.
mTOR inhibition in an in vivo murine experimental
model of TB
We then examined the in vivo effects of mTOR inhibition on
Mtb-induced cytokine responses. C57BL/6 mice were injected

Figure 1. Transcriptional regulation of glucosemetabolism during active TB disease and in PBMCs stimulated withMtb. (A, B) Principal component
analysis of the glycolysis and TCA cycle whole blood gene signatures of microarray data from publically available cohorts from (A) the United
Kingdom (UK) and (B) South Africa (SA), previously published by Berry et al. (Series GSE19444) [9]. Data for each sample, including active pulmonary
TB (PTB), LTBI (TST positive), and CON (TST negative) individuals were plotted along PC1 for glycolysis versus PC1 for the TCA cycle. For the UK
cohort, PC1 accounted for 37% of the total variation for both glycolysis and the TCA cycle. For the SA cohort PC1 accounted for 44 and 34% of the
variance for glycolysis and the TCA cycle respectively. (C–E) Individual and mean whole blood gene expression for (C) GAPDH, (D) hexokinase-3,
and (E) IDH3B in controls and PTB patients on 0, 2, or 12 months of TB treatment (Series GSE19435). Microarray data derived from Berry et al [9].
Symbols represent individual samples and data are shown as means ± SEM; means were compared using the Mann–Whitney U test. *p < 0.05,
**p< 0.01, ***p< 0.001. (F) Heatmap of gene expression pattern of glycolysis or TCA cycle genes in in vitro-stimulated PBMCs and in vivo whole blood
(UK and SA publically available cohorts). All data was log-2 transformed. The in vitro Mtb stimulations were normalized to RPMI by subtracting
means whereas the in vivo PTB cohort was normalized to the corresponding LTBI cohort. p-values were considered significant when less than 0.05
as determined by the Wilcoxon signed-rank test for the in vitro data set and by the Mann–Whitney U test for the in vivo data sets. Red represents
a significant up regulation, blue a significant down regulation and grey no difference. (G) Schematic representation of upregulated (in red) and
downregulated (blue) genes in the glycolysis and TCA cycle pathways as determined by microarray analysis of Mtb-stimulated PBMCs.
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Figure 2. Physiology of the PBMCmetabolic response to Mtb stimulation. (A, B) CD14+ monocytes were stimulated for 24 h with Mtb and (A) ECAR
and (B) OCR rates were determined using the Seahorse metabolic analyzer. Three baseline measurements were determined. Data are shown as
means ± SEM (n = 7). (C) Lactate production from macrophages stimulated with live H37Rv (10:1 MOI) was measured by a fluorescent coupled
enzymatic assay. Data are shown as means ± SEM of n = 4, pooled from two independent experiments. (D-F) PBMCs were stimulated with
Mtb lysate and the kinetics of (D) glucose consumption, (E) lactate production and (F) the intracellular NAD+/NADH ratios from days 1, 3 and 7
was measured by metabolite specific coupled enzymatic assays. Data are shown as means ± SEM of n = 6 to 8, pooled from three independent
experiments. Means were compared using the Wilcoxon signed-rank test, *p < 0.05).
Figure 3. Induction of glycolysis in human PBMCs is mediated by the AKT-mTOR pathway. (A–D) PBMCs were stimulated with RPMI or Mtb in a
time-dependent manner in the presence or absence of DMSO (vehicle control), wortmannin (PI3K/AKT inhibitor), or rapamycin (mTOR inhibitor).
(C) CD14+ and CD3+ T cells were separated from PBMCs stimulated for 2 h with Mtb. Where indicated, GM-CSF stimulation was included as a
positive control. (A, B) AKT, (C, D) p70-S6K and 4E-BP1 phosphorylation and actin levels were determined byWestern blot using specific antibodies.
(A, B) Cell lysates were harvested at 15, 30, 60, and 120 min poststimulation. (C, D) Cell lysates were harvested at 30, 60, 120, and 240 min
poststimulation. Representative blots from two of four donors are shown. (E–G) PBMCs were preincubated with 10 nM rapamycin, 100 nM torin,
or 100 nM wortmannin for 1 h prior to stimulation with Mtb lysate. Data are shown as means ± SEM of n = 9, pooled from three independent
experiments. Means were compared using the Wilcoxon signed-rank test (*p < 0.05, **p < 0.01).
C© 2016 The Authors. European Journal of Immunology published by
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Figure 4. mTOR regulation of Mtb-induced T-cell cytokine responses. (A–D) PBMCs were preincubated with DMSO (vehicle control) or (A) 1 mM
or 5 mM 2-deoxy-glucose, (B) 1 nM or 10 nM rapamycin, 100 nM torin, (C) 500 μM AICAR, or (D) 50 μM or 500 μM ascorbate or for 1 h prior to
stimulation with Mtb lysate. IL-17, IFN-γ, and IL-22 levels were measured from culture supernatants by ELISA. Data are shown as means ± SEM of
n = 6–9 pooled from three independent experiments. Means were compared using the Wilcoxon signed-rank test (*p < 0.05, **p < 0.01).
with rapamycin or control vehicle 1 day before aerosol infec-
tion with Mtb and thereafter daily for 28 days (Fig. 7A). At 28
day postinfection, ex vivo stimulations of splenocytes with Mtb
lysate, PPD, PHA, and LPS revealed a potent reduction in the
capacity of the rapamycin-treated mice to respond to both Mtb
lysate (Fig. 7B) and nonspecific stimuli such as PPD, PHA, and
LPS (Supporting Information Fig. 6A–V). Notably, the produc-
tion of the TH-derived cytokines IFN-γ and IL-17 was inhibited
by rapamycin (Fig. 7B), as previously observed in vitro. Systemic
inhibition of mTOR also led to the inhibition of proinflammatory
cytokines IL-12 p70 and TNF-α (Fig. 7B). It is highly likely that
due to the antimycobacterial effects of rapamycin [17], rapamycin
injections did not affect Mtb outgrowth (Supporting Information
Fig. 6W).
C© 2016 The Authors. European Journal of Immunology published by
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Figure 5. Role of NOD2 in the induction of glycolysis. (A, B) PBMCs from NOD2-deficient patients (n = 2) and healthy volunteers (n = 4) were
stimulated with RPMI, MDP, and Mtb for 24 h and 7 days. The levels of (A) indicated cytokines or (B) lactate production were measured from
culture supernatants by ELISA and an enzymatic couple assay, respectively. Data are shown as means ± SEM of the indicated number of donor
samples and are from a single experiment. (C, D) BMDMs fromWT, NOD1 knockout (−/−), NOD2 knockout (−/−), and NOD 1/2 double knockout (−/−)
mice were stimulated with RPMI or 1 μg/mL Mtb lysate for 24 h (n = 2). The levels of (C) IL-6 and KC and (D) lactate production were measured as
described above. Data are shown as means ± SEM of n = 2 from a single experiment.
Discussion
A metabolic switch to aerobic glycolysis, also known as the
Warburg effect, was first described by Otto Warburg in cancer
cells [18]. In recent years an increasing body of literature has
shown that a similar pattern of metabolic rewiring is impor-
tant for differentiation of effector TH lymphocytes [5], activation
of macrophages and DCs [1] and more recently for Mtb infec-
tion [7, 8]. Expanding on this, we used transcriptome data to
demonstrate that this switch takes place in patients with active
TB disease and we thereafter performed functional experiments
to identify the molecular mechanisms governing this switch to
glycolysis. Specifically, we show that the switch to glycolysis in
cells that encounter Mtb relies on TLR2 recognition and is in part
dependent on the intracellular AKT-mTOR axis.
Aerobic glycolysis is an ancient process for generating ATP
seen even in early single-cell eukaryotes such as yeast. Although
primitive in comparison to the TCA cycle and oxidative phospho-
rylation, aerobic glycolysis rapidly facilitates the high bioenergetic
needs of cells responding to intruding pathogens. We show that
this metabolic switch is also necessary for cells to mount an effi-
cient response to Mtb.
The mTOR regulatory complex has been highly conserved
throughout evolution. It integrates extracellular and intracellu-
lar signals to regulate cell growth, metabolism, proliferation, and
survival. The mTOR protein can form two distinct multiprotein
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2
(mTORC2). Mtb stimulation increased mTORC1 activity as mea-
sured by an increase in phosphorylation of its targets 4E-BP1 and
p70-S6K1. Additionally, rapamycin inhibits mTORC1 but cannot
C© 2016 The Authors. European Journal of Immunology published by
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Figure 6. Stimulation via TLR2 initiates rewiring of cellular metabolism in mouse macrophages. (A–C) PBMCs from healthy volunteers (n = 6) were
stimulated with RPMI, MDP ± LPS, Pam3Cys (P3C) or Mtb lysate for 24 h. The levels of (A) IL-1β, (B) IL-6, and (C) lactate in cell culture supernatants
were measured as described above. Data are shown as means ± SEM of n = 6 pooled from two experiments. Means were compared using the
Wilcoxon signed-rank test (*p < 0.05). (D, E) PBMCs were preincubated with TLR4 antagonist B. quintana LPS (20 and 100 ng/mL) prior to stimulation
with RPMI, Mtb lysate, or LPS. The levels of (D) IL-6 production and (E) lactate in culture supernatants were determined by ELISA and a coupled
enzymatic assay, respectively. Data are shown as means ± SEM of n = 6–8 pooled from three experiments. Means were compared using the
Wilcoxon signed-rank test (*p < 0.05). (F–H) BMDMs and peritoneal macrophages (Mfs) from TLR2 knockout (TLR2−/−) mice were stimulated with
RPMI, P3C (positive control) and Mtb lysate. The levels of (F) KC (IL-8) and (G, H) lactate in culture supernatants were measured by ELISA and a
coupled enzymatic assay. Data are shown as means ± SEM of n = 3–6 pooled from two experiments. Means were compared using the Wilcoxon
signed-rank test. (I) Levels of AKT activation fromTLR2−/− BMDMs stimulatedwith RPMI, insulin (control; INS) andMtb lysate (Mtb) was determined
by western blot. Actin was used as loading control. One of two representative blots is shown.
physically interact or acutely inhibit mTORC2. This suggests that
the Mtb-induced switch to aerobic glycolysis is in part due to
mTORC1 activation. The involvement of mTORC1 is further sup-
ported by studies showing that naive T-helper cells preserve their
ability to differentiate into TH1 and TH17 cells in the absence of
mTORC2 signaling, but not in the absence of mTORC1 signal-
ing [19]. Mechanistically, it would be highly interesting to deter-
mine whether mTORC2-deficient cells could commit to glycolysis.
Of note, blockade by rapamycin, torin, and wortmannin individ-
ually does not completely ablate lactate production suggesting
redundancy of these regulators, regulation by other pathways,
or incomplete pharmacological inhibition. Dissecting whether the
mTOR/AKT pathway is the sole regulator of glycolysis would
therefore be of future interest.
NOD2 and TLR receptors are major PRRs for Mtb, with syner-
gistic effects on Mtb-medicated cytokine production [20, 21]. It
is thus interesting that rewiring of cellular glucose metabolism is
strictly TLR2 dependent (but NOD2 independent), and that the
NOD2 agonist MDP does not potentiate TLR2-induced lactate pro-
duction. The discrepancy between the effects of NOD2 on cytokine
C© 2016 The Authors. European Journal of Immunology published by
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Figure 7. In vivo effects of mTOR inhibition. (A, B) C57/BL6 mice were treated with rapamycin or vehicle (mixed PBS/100% EtOH) from 1 day prior
to aerosol infection with Mtb until 28 days postinfection. Mice were euthanized and splenocytes were harvested and restimulated with Mtb lysate
(1 μg/mL) for 6 days, after which (B) a bead-based immunoassay for mTNF-α, mIL-12p70, mIIL-17, and mIFN-γ was performed. Data are shown as
means ± SEM of n = 6 samples from a single experiment. Means were compared using the Mann–Whitney U test (*p < 0.05).
responses and induction of glycolysis suggests the presence of dis-
tinct intracellular pathways responsible for these two processes.
While NOD2 stimulation is known to induce MAPK activation and
NF-kB translocation leading to cytokine induction [22], activation
of the AKT/mTOR pathway is not demonstrated. In contrast, TLRs
induce both MAPK, NF-κB, and the AKT/mTOR pathway [23, 24].
Moreover, activation of AKT inhibits the NOD2-mediated NF-κB
pathway [25], while NOD1 stimulation (that activates similar
intracellular pathways) inhibits AKT phosphorylation induced by
insulin [26]. These data strongly suggest a fundamental difference
between TLRs and NOD2 for activation of AKT/mTOR pathway,
with NOD2 unable to induce AKT activation and thus metabolic
reprogramming. Future studies that compare this requirement for
TLR2 in other infectious stimuli, such as Gram positive or negative
bacteria, would be of interest.
TH cells exert different effector functions and thus it is not sur-
prising that they exhibit distinct metabolic programs. T-effector
cells primarily rely on mTOR-driven aerobic glycolysis for energy,
while regulatory T cells rely on lipid oxidation and mitochondrial
respirationmediated by AMPK [1]. Mtb-induced TH17 cells appear
to be more dependent on aerobic glycolysis than TH1 cells, possi-
bly due to the upregulation of HIF-1α [27]. HIF-1α is a hypoxia-
induced transcription factor that directly controls gene expres-
sion of enzymes in the glycolysis pathway [28]. The role of HIF-
1α in the generation of IFN-γ-producing TH1 cells is unclear, as
either enhanced or no differences in IFN-γ production have been
observed in experimental models lacking HIF-1α [29, 30]. The use
of ascorbate, an HIF-1α inhibitor, emulates these observations, as
a significant decrease in IL-17 but not IFN-γ production was found
in PMBCs.
In vitro inhibition of mTOR with rapamycin or torin led to
either no differences or an increase in TNF-α, IL-6, and IL-1β
production, in line with literature showing that mTOR inhibits
proinflammatory cytokine production via negative regulation of
NF-κB, while inhibiting T-cell proliferation [31]. Nonetheless, in
our in vivo Mtb infection model, prolonged exposure to rapamycin
inhibited overall cytokine responses to Mtb including proinflam-
matory cytokines such as IL-12 and TNF-α. Likewise, 2-DG, a direct
competitive inhibitor of glycolysis, inhibited both monocyte and
T-cell-derived cytokines. As mentioned above, the HIF-1α
inhibitor ascorbate did not influence monocyte-derived cytokines,
in contrast to a previous study showing HIF-1α-dependent
LPS-mediated IL-1β production in murine macrophages [32].
This may be explained by the differences in required doses of
ascorbate, or discrepancies between human and mouse glucose
metabolic processes.
In this study, we take a step further in dissecting the role of
leukocyte energy metabolism in the immune responses to Mtb in
vitro and in vivo. Recognition of the fact that metabolic rewiring
toward glycolysis is crucial for host immunity leads to the hypoth-
esis that perturbations in leukocyte metabolism could be detri-
mental for the host. For instance, impaired glucose metabolism in
patients with diabetes leading to reduced capacity to mount the
necessary metabolic changes to respond to Mtb may contribute
significantly to their increase in TB susceptibility.
In conclusion, our study has cemented glycolysis as a funda-
mental process that underpins the cellular circuitry needed to
mount effective host responses to Mtb and promotes it as a ther-
apeutic target in TB. In particular, pharmacologic manipulation
of enzymes in these pathways may generate more robust and
effective immune responses and thus open up new avenues for
host-directed therapies for tuberculosis.
Materials and methods
Healthy volunteers
PBMCs were isolated from EDTA tubes or buffy coats obtained
after informed consent of healthy volunteers (Sanquin Blood-
bank, Nijmegen, Netherlands). As donations were anonymous, no
C© 2016 The Authors. European Journal of Immunology published by
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tuberculosis skin tests or IFN-γ release assay was performed. The
incidence of tuberculosis in the Dutch population is extremely low
(1.5/100 000), and Bacillus Calmette-Gue´rin (BCG) vaccination
is not part of the routine vaccination program. Experiments were
conducted according to the principles expressed in the Declaration
of Helsinki.
Isolation of PBMCs, CD14+ Monocytes and CD3+
T cells
Isolation of PBMCs was performed as described previously [33].
CD14+ monocytes or CD3+ T cells were purified from freshly iso-
lated PBMCs using MACS microbeads by positive selection accord-
ing to the manufacturer’s instructions (Miltenyi Biotec, Germany).
Stimulation experiments
For stimulation experiments, 5× 106 PBMCs/mL or 1× 106 mono-
cytes/mL were stimulated with RPMI, 1 μg/mL Mtb strain H37Rv
(Mtb) lysate, 10 μg/mL Pam3Cys (EMC Microcollections, Ger-
many) and/or 10 μg/mL MDP (Sigma) in the presence or absence
of 1 or 10 nM rapamycin (LC-laboratories), 100 nM Torin (Tocris),
50 or 500 μM sodium L-ascorbate (Sigma), 50 or 500 μM AICAR
(Brunschwig chemie), 100 nM wortmannin (Cayla Invivogen),
or 20 or 100 ng/mL of TLR4 inhibitory ligand double-extracted
B. quintana LPS for 24 h or with 10% pooled human serum for
7 days. PBMCs from patients with the homozygous carriage of
a frameshift in Nod2 due to an insertion of cysteine at position
1007 (1007finsC) (rs2066847) were stimulated with RPMI, MDP,
or Mtb for 1 or 7 days. Culture supernatants were collected and
stored at −20°C. For Western blots, 5 × 106 PBMCs were stimu-
lated with RPMI, 1 μg/mL Mtb lysate or 50 ng/mL GM-CSF in the
presence or absence of the aforementioned inhibitors. Cytokine
measurements from cell culture supernatants were performed by
ELISA namely IL-1β, TNF-α, IL-17A, IL-22 (R&D Systems, Min-
neapolis, MN); and IL-6, IFN-γ, and IL-10 (Sanquin, Amsterdam)
were measured.
Animal experiments
TLR2 knockout mice were kindly provided by Prof S. Akira
(Department of Host Defense, Research Institute for Microbial
Diseases, Osaka University, Osaka, Japan) and were fully back-
crossed to the C57BL/6 background. Age- and sex-matched control
C57BL/6 mice were obtained from Charles River Wiga (Sulzfeld,
Germany).
Wild-type, NOD1, NOD2, and NOD1/NOD2 double knock-
out mice were bred and maintained in the St. Jude Children’s
Research Hospital (Memphis, TN). After dissection of mouse legs,
the BM was flushed out using sterile PBS and cells obtained
were differentiated over a period of 7 days0 at 37°C, 5% CO2
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Invitro-
gen, Carlsbad, CA, USA) supplemented with 30% L929 medium,
10%heat-inactivated filtered foetal bovine serum (Invitrogen), 1%
nonessential amino acids (Life Technologies), 100 U/mL penicillin
and 100 mg/mL streptomycin. On day 6 BMDMs were washed,
counted, and seeded in 96-well plates at a concentration of 1 ×
105 cells/well or in 6-well plates at 1 × 106 cells/well for West-
ern blotting. Cells were left to rest overnight at 37°C, after which
they were stimulated with medium, namely 10 μg/mL Pam3Cys,
1 μg/mL Mtb or 100 nM insulin. Experiments were approved by
the Ethics Committee on Animal Experimentation of the Radboud
University Medical Center and protocols were approved by the St.
Jude Children’s Research Hospital Committee on the Use and Care
of Animals.
Female 8- to 10-week-old C57BL/6 mice were kept under
pathogen-free conditions at the Max Planck Institute for Infec-
tion Biology in Berlin, Germany (ethical approval of the Berlin
Office for Health and Social Affairs reference number G 0179/12).
Mtb strain H37Rv was grown in Middlebrook 7H9 broth (BD Bio-
sciences) supplemented with 0.2% glycerol, 0.05% Tween 80,
and 10% ADC enrichment (BD Biosciences) until it reached a
mid-logarithmic growth phase and then stored at –80°C. Animals
were aerosol infected with 200 CFUs using a Glas-Col inhala-
tion exposure system. Rapamycin (Sigma) or vehicle (PBS/100%
EtOH) was injected the day before aerosol infection and thereafter
daily for 28 days. Splenocytes were isolated from single-cell sus-
pensions prepared by mechanical dissociation through a 70 μm
nylon mesh in RPMI 1640 medium with 10% foetal calf serum
(Gibco). Splenocytes were seeded in a 24-well-plate at a con-
centration of 2.5 × 106 cells /mL and stimulated with 1 μg/mL
of Mtb lysate, 1 μg/mL of PPD (Staten Serum Institut, Copen-
hagen), 10 μg/mL PHA (Sigma) or 10 ng/mL of LPS (from E.
coli 055:B5, Sigma). After 6 days supernatants were collected and
stored at –20°C. Cytokines were analyzed using a bead-based assay
(Bio-Rad).
Metabolite measurements
Lactate was measured from cell culture supernatants using a cou-
pled enzymatic assay in which lactate was oxidized and the result-
ing H2O2 was coupled to the conversion of Amplex Red reagent
to fluorescent resorufin by HRP (horseradish peroxidase) [34].
Measurement of the NAD+/NADH redox ratio was adapted from
Zhu et al. [35]. Glucose consumption was measured according
to the manufacturer’s instructions using the Amplex Red Glu-
cose/Glucose Oxidase Assay Kit (Life Technologies).
Real-time analysis of the ECAR and the OCR on CD14+ mono-
cytes was performed using an XF-96 Extracellular Flux Analyzer
(Seahorse Bioscience). Briefly, monocytes were plated in XF-96
cell culture plates (2 × 105 monocytes/well) in the presence
of RPMI or Mtb lysate for 24 h in 10% human pooled serum.
The monocytes were washed and analyzed in XF Base Medium
(unbuffered DMEM with 25 mM glucose and 2 mM L-glutamine,
pH was adjusted to 7.4). Basal OCR and ECAR of the monocytes
was measured every 5 min for 20 min in total.
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Cell viability assessment
The percentage of cells that underwent early or late apop-
tosis was determined by labeling with annexin V–fluorescein
isothiocyanate (FITC, Biovision) and staining with propidium
iodide (PI, Sigma Aldrich), according to the manufacturer’s
instructions. Briefly, stimulated PBMCs were resuspended in
200 μL of RPMI and incubated on ice in the dark with 1 μL of
Annexin V-FITC for 15 min followed by a 5 min incubation with
1.5 μL of PI. The relative level of apoptotic cells was detected by
flow cytometry within 1 h, using a FC500 flow cytometer (Beck-
man Coulter) and data were analyzed using Kaluza 1.3 software
(Beckman Coulter).
Western blotting
Western blotting was carried out using a Trans Turbo Blot system
(Bio-Rad) according to the manufacturer’s instructions. A total of
5 × 106 PBMCs or 1 × 106 CD14+ monocytes or 1 × 106 CD3+
T cells were lysed in 100 μL lysis buffer. The cell homogenate was
frozen, thawed, and processed for Western blot analysis. Equal
amounts of protein were resolved by SDS-PAGE on 4–15% poly-
acrylamide gels (Bio-Rad). Separated proteins were transferred
to PVDF (Bio-Rad) membranes. According to the manufacturer’s
instructions, the membrane was blocked for 1 h and then incu-
bated overnight with a primary antibody at a dilution of 1:1000 in
5%w/v bovine serum albumin (BSA, Sigma) ormilk in TBS-Tween
buffer (TBS-T). After overnight incubation, blots were washed in
TBS-T three times and incubated with HRP-conjugated anti-rabbit
antibody (1:5000; Sigma) in 5% w/v milk in TBS-T for 1 h at
RT. After washing the blots were developed with ECL (Bio-Rad)
according to the manufacturer’s instructions. The primary anti-
bodies used were rabbit anti-actin (Sigma), mAB phospho-p70 S6
Kinase (Thr389) (Cell Signalling), phospho-AKT (Cell Signalling),
and phospho-4EBP1 (Cell Signalling).
Transcriptome analyses
We obtained previously published transcriptome data for our anal-
ysis (GSE42606) [36] Briefly, PBMCs were stimulated with RPMI
or Mtb (1 μg/mL) for 24 h at 37°C and 5% CO2. Total RNA
was extracted in 800μL of TRIzol reagent (Invitrogen). Global
gene expression was profiled using an Illumina Human HT-12
Expression BeadChip according to themanufacturer’s instructions.
Image analysis, bead-level processing, and quantile normalisa-
tion of array data were performed using the Illumina LIMS plat-
form, BeadStudio. The quantile normalized expression data for
glycolysis and TCA cycle genes (derived from KEGG pathway)
were extracted to perform differential expression analysis between
RPMI and Mtb stimulations.
Human gene expression analysis
Publicly available microarray data (Illumina Human HT-12 V3
BeadChip) from cohorts of patients with active and latent tubercu-
losis and uninfected controls in the UK and South Africa [9]) were
obtained from the Gene Expression Omnibus (GEO) under acces-
sion number GSE19491. We restricted our analysis to the expres-
sion data from whole blood (collected in Tempus tubes, Applied
Biosystems) from the UK test cohort and the South-African valida-
tion cohort. Genes implicated in glycolysis (path:hsa00010) and
TCA cycle (path:hsa00020) pathways were extracted from KEGG,
putative genes were removed and the remaining genes were
converted into Illumina probe numbers using DAVID [37, 38].
Probes that had a negative expression for one of the samples were
excluded.
Statistical Analysis
Principal component analysis was performed on log-transformed
data using singular value decomposition separately for the glycol-
ysis and TCA cycle pathways in Python. Scores of the samples pro-
jected on principal component (PC) 1 for glycolysis were plotted
against the scores on PC1 for the TCA cycle, to show the maximum
combined variance of both pathways in one graph. Additionally,
binary regression analysis was performed on the scores projected
on PC1 for both pathways with LTBI (0) versus PTB (1) for the
South-African cohort in SPSS 21.
The heat maps show differences in expression based on log2
transformed data from the different groups. Statistical testing
of the in vitro data set was performed on the mean expression
between the unstimulated (RPMI) and stimulated (Mtb) samples
using a Wilcoxon signed-rank test for parametric data; adjusted
p-values less than 0.05 were considered significant. LTBI versus
PTB patients were compared using Mann–Whitney U tests. Color
coding was based on the minimum and maximum for each of
the comparisons. In the legend, changes were transformed back
for interpretability. Genes that showed a differential expression in
any of the datasets are presented in the figure.
Differences in cytokine production were analyzed using the
Wilcoxon signed-rank test for nonparametric distributions. Data
were considered statistically significant at a p-value < 0.05. Data
are shown as cumulative results of levels obtained in all volunteers
(means ± SEM).
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